Policy & Regulation
Hikma wins final ruling in Amarin's Vascepa generic patent lawsuit Decision expected to bolster 'skinny label' practice for early generic launches

The U.S. Supreme Court sided with the generic drug industry's early-market launch strategy known as a "skinny label," ruling against originator drugmaker Amarin.
According to BioPharma Dive on the 5th (local time), the U.S. Supreme Court unanimously ruled 9-0 that generic drugmaker Hikma Pharmaceuticals did not violate patent law in Amarin's patent infringement lawsuit involving its cardiovascular drug Vascepa.
A "skinny label" is a strategy in which a generic drug is approved only for certain indications whose patents have expired among the multiple indications of the originator drug, allowing the generic to launch early. Generic drugmakers have argued that it is an essential approach for promoting lower drug prices and competition in response to originator companies' strategies to extend patent protection.
Vascepa, at the center of the lawsuit, is a prescription drug containing a purified fish-oil ingredient. It was first approved in 2012 to lower blood triglyceride levels and received an additional indication in 2019 to prevent heart attacks and strokes in patients at high risk of cardiovascular disease.
Hikma launched a generic version of Vascepa in the United States in 2023, specifying that the drug was to be used only to lower triglyceride levels and was not approved for the other indication. Amarin, however, sued Hikma, alleging that the company had "induced infringement" by enabling the drug to be used to reduce cardiovascular risk.
The Delaware District Court previously dismissed Amarin's lawsuit, but the appellate court overturned that decision, drawing attention to the Supreme Court's final ruling. The Supreme Court determined that most of Hikma's conduct that could be viewed as encouraging infringing use consisted of legally required actions, while its other conduct was too ambiguous to constitute an "affirmative step" toward an improper use.
Legal experts said the ruling will significantly raise the bar for future lawsuits involving "skinny labels." Randy McCarthy, head of intellectual property at the law firm Hall Estill, said, "The Supreme Court's decision substantially redefined and strengthened the requirements for induced infringement," adding, "It will be much more difficult to prove this in future litigation."
Meanwhile, Vascepa is Amarin's only marketed product, and the company recorded sales of approximately $214 million (about 308.1 billion won) in 2025.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
MFDS to Use AI for Vaccine Release and Process Validation, Shifting From Post-Production Testing to Real-Time Prediction

Tandem’s tubeless insulin pump wins FDA approval, with wear time of up to 7 days

‘Speed Race’ for Innovative Medical Devices Stalls at Health Insurance Reimbursement Hurdle

The ‘Valley of Death’ for Infectious Disease Treatments: Cross-Agency Coordination Is Key

Mounjaro Costs 59,000 Won in Japan, 300,000 Won in Korea, Sparking Price Debate

SME Ministry aims to develop 20 AI startups valued at 1 trillion won by 2030